As it has been reported that patients with HER2+ invasive cancer have a poorer prognosis than those whose tumours do not express HER2,61 the higher incidence of expression found in DCIS may therefore seem paradoxical. Here, ERBB2 is linked to ductal breast carcinoma in situ.